Crescent Biopharma (CBIO)Director bought ~$18.2M
Fairmount Funds Management LLC, Director at Crescent Biopharma, bought ~$18.2M of Crescent Biopharma shares.
- ~$18.2M
- Approx. value · 1.36M sh @ $13.41
- 2.75M
- Holds after · shares reported
- Traded
- Dec 4, 2025
- Filed
- Dec 8, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Nov 6, 2025Company filing · Form 8-K · ResultsReported its results
- Dec 2, 2025Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 2 more items)
- Dec 4, 2025 · this disclosureInsider · Largest insider buy since 2014Director purchased ~$18.2M of CBIO shares in the open market
What came next
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Crescent Biopharma
For Crescent Biopharma, OQRO holds 10 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CBIO page.
Other recent filings by Fairmount Funds Management LLC, Director
- SEC Form 4 at Crescent Biopharma (CBIO)Jul 20, 2026
- SEC Form 4 at Cogent Biosciences (COGT)Jul 14, 2025
The full history of Fairmount Funds Management LLC, Director is on the profile page.
How this filing works
Other disclosures at Crescent Biopharma
- SEC Form 4Sep 18, 2026
- SEC Form 4Sep 18, 2026
- SEC Form 4Sep 18, 2026
- SEC Form 4Sep 18, 2026
- SEC Form 4Sep 18, 2026
- SEC Form 4Sep 18, 2026
Everything OQRO holds on this company is on its CBIO page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data